PARP inhibitors "Jejula" and "Lynparza" are expected to be applied to primary maintenance therapy for ovarian cancer as early as the third quarter. This is limited to BRCA mutations, and most patients without mutations do not benefit.

According to the pharmaceutical industry on the 21st, Takeda followed by Lynparza (Olaparib) of AstraZeneca.The pharmaceutical company Zejula (Niraparib) also passed the Pharmaceutical Benefits Advisory Committee of the HIRA and is in negotiations with the NHIS.

It is predicted that both products will complete the process of registering their benefits in third quarter. 80 to 90% of all ovarian cancer patients with BRCA negative effects will be excluded from